Downstream Development Challenges and Progress for AAVs

The development of innovative advanced therapies represents a great opportunity to dramatically improve patients’ lives. However, the rapid and efficient production of these advanced therapies remains a considerable challenge. In this poster, we discuss our recent technological advancements in the process development of viral vector manufacturing. From clarification to separation of empty and full capsids, each downstream processing step has its challenges in viral vector manufacturing at a CDMO. As we continue to make progress for AAV, a series of programs were implemented to advance our scalable large scale manufacturing AAV viral vector platform.

Download your copy today!

CLICK HERE to Download

CLICK HERE to learn more about WuXi Advanced Therapies